{"id":22743,"date":"2023-01-17T18:11:00","date_gmt":"2023-01-17T10:11:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22743"},"modified":"2025-01-23T18:13:27","modified_gmt":"2025-01-23T10:13:27","slug":"affamed-secures-china-rights-to-eli-lillys-migraine-drug-galcanezumab","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22743","title":{"rendered":"AffaMed Secures China Rights to Eli Lilly&#8217;s Migraine Drug Galcanezumab"},"content":{"rendered":"\n<p>China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole commercialization rights for galcanezumab in mainland China. The monoclonal antibody, developed by Eli Lilly, selectively binds to the calcitonin gene-related peptide (CGRP) and was approved by the FDA in September 2018 for the preventive treatment of migraines in adults. It was also approved in June 2019 for the treatment of episodic cluster headaches in adults. Galcanezumab is currently used for migraine treatment in 20 countries worldwide.<\/p>\n\n\n\n<p><strong>Clinical Data and Market Potential<\/strong><br>Galcanezumab is the first and only medication approved by the US FDA to reduce the number of attacks for episodic cluster headaches. Eli Lilly submitted a new drug application for galcanezumab as a preventative treatment for episodic migraines in adults to the National Medical Products Administration (NMPA) in June 2022. Migraine headaches are a disabling neurologic disease affecting nearly one in every ten Chinese, with an estimated 130 million prevalent cases, of which approximately two-thirds are women. Despite their high prevalence, migraines remain under-recognized and under-treated in China.<\/p>\n\n\n\n<p><strong>Phase III PERSIST Study Results<\/strong><br>In the Phase III PERSIST study, a randomized, double-blind, placebo-controlled pivotal trial assessing the efficacy and safety of galcanezumab in patients with episodic migraines in China, India, and Russia, galcanezumab demonstrated significant efficacy. The least squares (LS) mean reduction from baseline in monthly migraine headache days (MHDs) over three months was significantly greater with galcanezumab compared to placebo (-3.81 days vs. -1.99 days; p &lt; 0.0001). Additionally, significantly greater mean proportions of patients with galcanezumab versus placebo achieved \u2265 50%, \u2265 75%, and 100% reductions from baseline in MHDs (all p &lt; 0.0001).<\/p>\n\n\n\n<p><strong>Future Outlook<\/strong><br>With this agreement, AffaMed is poised to bring galcanezumab to the Chinese market, addressing a significant unmet need for effective migraine prevention. The partnership underscores AffaMed&#8217;s commitment to improving patient outcomes and expanding access to innovative therapies in China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2127,87,199],"class_list":["post-22743","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-affamed-therapeutics","tag-chronic-disease","tag-eli-lilly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AffaMed Secures China Rights to Eli Lilly&#039;s Migraine Drug Galcanezumab - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole commercialization rights for galcanezumab in mainland China. The monoclonal antibody, developed by Eli Lilly, selectively binds to the calcitonin gene-related peptide (CGRP) and was approved by the FDA in September 2018 for the preventive treatment of migraines in adults. It was also approved in June 2019 for the treatment of episodic cluster headaches in adults. Galcanezumab is currently used for migraine treatment in 20 countries worldwide.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22743\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AffaMed Secures China Rights to Eli Lilly&#039;s Migraine Drug Galcanezumab\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22743\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-17T10:11:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-23T10:13:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22743#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22743\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AffaMed Secures China Rights to Eli Lilly&#8217;s Migraine Drug Galcanezumab\",\"datePublished\":\"2023-01-17T10:11:00+00:00\",\"dateModified\":\"2025-01-23T10:13:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22743\"},\"wordCount\":317,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AffaMed Therapeutics\",\"Chronic disease\",\"Eli Lilly\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22743#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22743\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22743\",\"name\":\"AffaMed Secures China Rights to Eli Lilly's Migraine Drug Galcanezumab - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-17T10:11:00+00:00\",\"dateModified\":\"2025-01-23T10:13:27+00:00\",\"description\":\"China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole commercialization rights for galcanezumab in mainland China. The monoclonal antibody, developed by Eli Lilly, selectively binds to the calcitonin gene-related peptide (CGRP) and was approved by the FDA in September 2018 for the preventive treatment of migraines in adults. It was also approved in June 2019 for the treatment of episodic cluster headaches in adults. Galcanezumab is currently used for migraine treatment in 20 countries worldwide.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22743#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22743\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22743#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AffaMed Secures China Rights to Eli Lilly&#8217;s Migraine Drug Galcanezumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AffaMed Secures China Rights to Eli Lilly's Migraine Drug Galcanezumab - Insight, China&#039;s Pharmaceutical Industry","description":"China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole commercialization rights for galcanezumab in mainland China. The monoclonal antibody, developed by Eli Lilly, selectively binds to the calcitonin gene-related peptide (CGRP) and was approved by the FDA in September 2018 for the preventive treatment of migraines in adults. It was also approved in June 2019 for the treatment of episodic cluster headaches in adults. Galcanezumab is currently used for migraine treatment in 20 countries worldwide.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22743","og_locale":"en_US","og_type":"article","og_title":"AffaMed Secures China Rights to Eli Lilly's Migraine Drug Galcanezumab","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22743","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-17T10:11:00+00:00","article_modified_time":"2025-01-23T10:13:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22743#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22743"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AffaMed Secures China Rights to Eli Lilly&#8217;s Migraine Drug Galcanezumab","datePublished":"2023-01-17T10:11:00+00:00","dateModified":"2025-01-23T10:13:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22743"},"wordCount":317,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AffaMed Therapeutics","Chronic disease","Eli Lilly"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22743#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22743","url":"https:\/\/flcube.com\/?p=22743","name":"AffaMed Secures China Rights to Eli Lilly's Migraine Drug Galcanezumab - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-17T10:11:00+00:00","dateModified":"2025-01-23T10:13:27+00:00","description":"China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole commercialization rights for galcanezumab in mainland China. The monoclonal antibody, developed by Eli Lilly, selectively binds to the calcitonin gene-related peptide (CGRP) and was approved by the FDA in September 2018 for the preventive treatment of migraines in adults. It was also approved in June 2019 for the treatment of episodic cluster headaches in adults. Galcanezumab is currently used for migraine treatment in 20 countries worldwide.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22743#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22743"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22743#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AffaMed Secures China Rights to Eli Lilly&#8217;s Migraine Drug Galcanezumab"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22743"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22743\/revisions"}],"predecessor-version":[{"id":22744,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22743\/revisions\/22744"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}